A patient with sporadic Creutzfeldt-Jakob disease, a rare brain illness caused by an infectious prion, will receive an investigative treatment called PRN100, an antibody developed by researchers at University College London. "As this is the first time this treatment has been used in humans, we cannot predict what the outcome will be, but laboratory testing has shown the potential to treat prion infection," said Dr. John Collinge.